Abstract
Pravastatin is reported to increase the adiponectin level in humans, but the mechanism remains unclear. We examined plasma and gene expressions of adiponectin, tumor necrosis factor (TNF)-α, interleukin (IL)-6 and protein carbonyl level, an indicator of oxidative stress, in visceral and subcutaneous adipose tissue from 32 patients with coronary artery disease undergoing coronary artery bypass grafting (CABG). Fourteen patients with serum LDL-cholesterol level >100 mg/dl were treated with pravastatin at 10 mg/day for 2 months before CABG (Statin), and the other 18 with LDL-cholesterol ≤100 mg/dl were not (Control). The plasma adiponectin level was higher in the Statin than the Control group ( P < 0.05), but TNF-α and IL-6 levels were not different. Adiponectin gene expression in visceral tissue was 3-fold higher in the Statin than the Control group ( P < 0.01), but was not different in subcutaneous tissue. TNF-α and IL-6 gene expressions in each tissue were not different between the 2 groups. Protein carbonyl levels in plasma and visceral tissue were lower in the Statin than the Control group (both, P < 0.05). Thus, adiponectin expression and generation in visceral adipose tissue is increased in men with coronary artery disease treated with pravastatin. Pravastatin-initiated attenuation of oxidative stress could be involved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
